India has taken a significant step toward introducing its first dengue vaccine, as Subject Expert Committee (SEC) has recommended approval of Takeda’s dengue vaccine, Qdenga. The recommendation comes with a key condition: the company must conduct a post-marketing study to monitor the vaccine’s safety and effectiveness in real-world settings.
According to reports, this recommendation will now be reviewed by the national drug regulator CDSCO before a final decision on approval and rollout is made.
Qdenga (TAK-003), developed by Takeda, is a live attenuated tetravalent dengue vaccine designed to provide protection against all four dengue virus serotypes (DENV-1, DENV-2, DENV-3, and DENV-4).
The vaccine is administered in a two-dose schedule, typically spaced three months apart. It has already been approved in several countries, including regions in Asia, Latin America, and Europe.
Clinical trial data suggest that Qdenga provides protection against symptomatic dengue and reduces the risk of hospitalization. Studies indicate:
Sustained protection for several years after vaccination
Reduction in severe dengue cases
Protection across multiple serotypes, though efficacy may vary by serotype3
However, like other dengue vaccines, it is not considered a complete solution, and its effectiveness may depend on prior exposure to the virus.
Qdenga has been approved in various countries for individuals aged 4 years and above, though eligibility criteria in India will be finalized after regulatory approval.
The vaccine is intended for use in both individuals with and without prior dengue infection, which distinguishes it from earlier dengue vaccines that had more restrictive indications.
A key condition imposed by the expert committee is the requirement for a post-marketing surveillance study.
This study will:
Monitor long-term safety in the Indian population
Evaluate real-world effectiveness
Identify rare or delayed adverse events
Such studies are critical for vaccines introduced in populations with high disease burden and diverse epidemiological patterns.
Dengue remains a major public health challenge in India. According to data from National Center for vector borne diseases control1 indicates,
India reports almost 2 lakh dengue cases annually
In 2025, 113250 cases were reported.
Deaths vary annually but can range in the hundreds to over a thousand depending on outbreaks. 2025 had 95 deaths from dengue in India.
The Indian Journal of Medical Research highlights that dengue transmission has expanded geographically, with both urban and rural areas affected.
Dengue in India has shown changing patterns over time:
Increased frequency of outbreaks
Expansion into previously unaffected regions
Circulation of multiple serotypes simultaneously
Seasonal peaks, especially during monsoon and post-monsoon periods
These trends increase the complexity of disease control and highlight the need for preventive strategies, including vaccination.
While Qdenga represents a significant advancement, experts emphasize that it is not a standalone solution.
Dengue control will still depend on:
Vector control measures (mosquito management)
Public awareness and sanitation
Early diagnosis and clinical management
Vaccination, if approved, would likely be integrated as part of a broader dengue control strategy.
The expert panel’s recommendation of Takeda’s Qdenga vaccine marks a pivotal moment in India’s fight against dengue.
As India continues to face a growing dengue burden, the introduction of a vaccine could play an important role in reducing disease severity and hospitalizations, provided it is supported by robust surveillance and public health measures.
References
National Centre for Vector Borne Disease Control (NCVBDC). 2026. Dengue Situation in India. Ministry of Health and Family Welfare, Government of India. Accessed April 1, 2026.
Indian Journal of Medical Research (IJMR). 2023. “Dengue in India.” Indian Journal of Medical Research. Accessed April 1, 2026.
Takeda Pharmaceutical Company Limited. 2025. “Takeda Announces Progress on Dengue Vaccine (Qdenga).” Accessed April 1, 2026.